Five phar­mas back $85M Se­ries A for Me­di­ar's fi­bro­sis-mod­u­lat­ing an­ti­bod­ies

Me­di­ar Ther­a­peu­tics nabbed $85 mil­lion to get in the clin­ic next year with its first an­ti­body meant to mod­u­late fi­bro­sis, hence the biotech’s name (in the form of Span­ish).

The Cam­bridge, MA start­up aims to cre­ate more pre­cise treat­ments for fi­bro­sis by go­ing af­ter tar­gets as­so­ci­at­ed with dis­ease sever­i­ty and that can be mea­sured in plas­ma, CEO Rahul Bal­lal told End­points News. Bal­lal said the biotech is ex­plor­ing a num­ber of in­di­ca­tions as fi­bro­sis spans many ar­eas: liv­er, lung, re­nal and car­diac.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER